Wild Biotech

Executive Summary

Wild Biotech is an Israeli biotech startup leveraging a proprietary database of microbial genes from extremophile animals, combined with AI and synthetic biology, to discover novel miniprotein and peptide therapeutics. The platform targets immune-modulating and cardiometabolic indications, aiming to develop orally bioavailable, low-immunogenicity biologic-like drugs. Founded in 2020, the company operates in preclinical stage with 10-50 employees and is privately held. The company's unique approach harnesses the vast genetic diversity of organisms that thrive in extreme environments, providing a rich source of stable and potent therapeutic candidates. By focusing on minimal scaffolds, Wild Biotech seeks to overcome common limitations of biologics, such as poor oral bioavailability and immunogenicity. With no disclosed funding or valuation, the company appears to be at an early developmental phase. Its success hinges on advancing lead candidates through preclinical validation and securing financing to support IND-enabling studies. If successful, Wild Biotech's platform could yield a pipeline of differentiated drugs for chronic diseases with high unmet need.

Upcoming Catalysts (preview)

• H2 2026Lead optimization completion and candidate nomination for immune-modulating program50% success
• TBDSeries A financing round60% success
• H2 2026In vivo proof-of-concept data for cardiometabolic lead candidate40% success